PAVmed Inc.

PAVM Healthcare Medical Devices

PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024.

Revenue
+450.0%
EPS
+96.1%
Free cash flow
−125.6%

Quarter to June 2026, against a year earlier

1.57 0.02 +1.29%
Market cap
$12.4M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
2/9
Altman Z
−11.40
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
2 5 4 — — — — — — —
P/E ratio
1.25 0.23 0.00 0.00 0.00 — — — — —
P/S ratio
83.81 2.03 10.57 56.94 0.00 — — — — —
Altman Z-Score
(11.40) (17.54) (20.03) (10.89) 10.12 — — — — —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 — — — — —
Altman Z″-Score (non-manufacturers)
(26.17) (44.18) (49.26) (24.52) 7.29 — — — — —
P/Operating CF
(3.84) 64.58 (2.18) (2.29) (10.04) — — — — —
P/B ratio
0.00 0.00 0.00 4.68 2.19 — — — — —
EV/Sales
109.24 2.75 3.93 0.96 0.00 — — — — —
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 — — — — —
EV/FCF
(1.59) (0.25) (0.19) (0.01) (2.49) — — — — —
Current Ratio
0.17 0.06 0.45 1.07 10.93 0.94 0.55 0.77 0.64 0.62
Net Debt/EBITDA
0.07 0.03 0.30 0.45 1.43 0.74 0.44 0.92 (0.05) 0.10
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (0.68) 0.00
ROE
59.31% (171.12%) 706.05% (209.45%) (136.86%) 695.15% 292.38% 447.03% 495.14% (3,590.15%)
ROA
(10.86%) 100.24% (152.17%) (126.66%) (94.85%) (255.85%) (212.59%) (369.98%) (828.50%) (542.18%)
ROIC
(65.64%) 0.00% 0.00% 0.00% (1,573.87%) 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
30.93% (96.48%) 237.56% (1,724.24%) (66.04%) 2,814.58% 313.77% 757.27% 1,150.11% 1,313.25%
Average Days of Receivables
77.11 2.19 9.08 16.46 146.00 — — — — —
Earnings Yield
79.91% 436.97% (260.14%) (233.22%) (28.53%) — — — — —
Free Cash Flow Yield
(82.12%) (547.85%) (197.80%) (188.14%) (24.96%) — — — — —
Free Cash Flow per Share
(7.81) (103.16) (212.95) (366.84) (244.25) (208.43) (199.46) (178.07) (220.45) (155.44)
Book value per Share
33.26 (21.81) (99.74) 55.31 461.20 (4.49) (69.12) (50.02) (94.95) (11.08)
Free Cash Flow
(5.24) (33.26) (51.28) (72.52) (42.06) (21.97) (13.38) (8.81) (6.61) (4.48)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 — — — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026